Accuray Incorporated

ARAY Healthcare Medical Devices

Accuray Incorporated’s revenue for fiscal 2026 (year ended June 2026) was $401.9 million, down 12.3% from fiscal 2025. In the quarter to June 2026, revenue fell 20.9%, EPS fell 300.0%, free cash flow grew 117.8% and total debt rose 18.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.16 0.01 −5.88%
Market cap
$20.8M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
1/9
Altman Z
−0.78
Beneish M
−3.08
Dividend safety
n/a

Accuray Incorporated (ARAY) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Accuray Incorporated (ARAY) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from 0.3× (March 2026) to 2.2× (April 2015); the current reading is higher than 1% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2026 0.3× (24.35%)
FY2025 0.5× (25.00%)
FY2024 0.6× (40.09%)
FY2023 1.0× 63.62%
FY2022 0.6× (48.22%)
FY2021 1.2× 72.21%
FY2020 0.7× (30.61%)
FY2019 1.0× 4.30%
FY2018 0.9× 8.84%
FY2017 0.9× (17.23%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 0.3× 1.49%
Mar 2026 0.3× (19.39%)
Dec 2025 0.4× (28.29%)
Sep 2025 0.6× 28.96%
42 more quarters

Against its own ten years

Low 0.3× High 2.2×
Ten-year median 0.9×
Current reading's percentile 1

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ARAY